Therion Biologics Corp. is moving its lead vaccine candidate into Phase III work. The Cambridge, Mass.-based company plans to begin this summer a trial evaluating Panvac-VF in metastatic pancreatic cancer patients who have failed treatment with gemcitabine. The FDA signed off on the study, which will be conducted under the agency's special protocol assessment (SPA) program. (BioWorld Today)

Therion Biologics Corp. is moving its lead vaccine candidate into Phase III work. The Cambridge, Mass.-based company plans to begin this summer a trial evaluating Panvac-VF in metastatic pancreatic cancer patients who have failed treatment with gemcitabine. The FDA signed off on the study, which will be conducted under the agency's special protocol assessment (SPA) program. (BioWorld Today)